Abstract library

203 results for "cytokeratin 19".
#1689 The Prognostic Value of the Expression of Cytokeratin 7 and 19 in Lungs and Pancreas Neuroendocrine Tumors
Introduction: The expression of cytokeratins (CK) 7,19 rarely occurs in the low grade neuroendocrine tumors (NET) of lung and pancreas. It is known that part of the low grade typical (TC) and atypical (ATС) carcinoids of lung and pancreas (pNET-G1,G2) can progress quickly and to metastasize. It is important to distinguish NET with a less differentiated cells immunophentype.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Iya A Voronkova
#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression
Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: MD Larisa Gurevich
#239 CK 19 Expression in Pancreatic Neuroendocrine Tumors as Negative Prognostic Factor and a Risk Factor for Metastases
Introduction: Neuroendocrine tumors (NET) of the pancreas are slow growing neoplasms, but they can metastasize after many years after surgery.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Larisa Gurevich
#1402 Merkel Cell Carcinoma of Lymph Node Without Skin Primary Can - and Should - Be Distinguished from Others Metastatic Neuroendocrine Carcinoma
Introduction: Merkel cell carcinoma of lymph node without primary tumour (MCCNWP) is a rare tumour which can be misinterpreted as lymph node metastasis (LNM) from a high-grade neuroendocrine carcinoma (NEC) on histological examination. However, this distinction is crucial for therapeutic management.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Prof. Serge Guyetant
#88 EpCam expression and detection of circulating tumor cells in neuroendocrine tumors
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated according to expression of EpCAM and cytokeratins 8, 18 or 19 and the absence of the haemopoietic marker CD45. The number of CTCs detected in 7.5 mls blood has been shown to correlate with prognosis in breast, colon and prostate cancer and can predict response to therapy. Neuroendocrine tumors (NETs) have not previously been reported to express EpCAM and have not been systematically assessed for presence of CTCs. We have therefore explored the expression of EpCAM in NETs and the detection of NET cells in the circulation.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#77 Angiogenesis markers after hepatic artery embolization of liver metastases in patients with neuroendocrine tumors
Introduction: In the event of diffuse hepatic metastases, hepatic artery embolization (HAE) can be a successful treatment option in patients with well-differentiated neuroendocrine tumors (WNET). Although there are suggestions of activation of the angiogenesis by HAE, no information is available about the development of growth factors caused by vascular obstruction with embolization.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MSc Catharina M Korse
Authors: Korse C M, Bonfrer J M, Taal B G, ...
#368 The Role of Image and Chromogranin A Level at Diagnosis: A Portuguese Review of 19 Patients
Introduction: Neuroendocrine tumors (NET) constitute a heterogeneous group of neoplasms. Biochemical neuroendocrine markers offer high sensitivity in establishing the diagnosis and, if correlated with image assessment, can provide important prognostic information.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Pedro Barata
#1258 Expressions of CK 19 and CD117 in Hepatic Metastatic Pancreatic Nonfunctional Neuroendocrine Neoplasms
Introduction: The expressions of CK19 and CD117 in pancreatic neoruendocrine neoplasms were considered dismal prognostic factors in some studies, but inconsistent in others.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Bao Xin
Authors: Xin B, Lou W, Ji Y, Xie Y, ...
Keywords: CK19, CD117, pNEN, LM, TMA
#1294 The Efficacy and Safety of Sunitinib in Heavily Pretreated Patients with NETs. National Cancer Research Center Experience.
Introduction: There was done monocentral trial. 19 pts with progressive well differentiated NETs (G1,G2) were treated with sunitinib
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Anastacia Odintsova
#272 Plasma Chromogranin A in Patients with MEN I and Pancreatic Endocrine Tumors
Introduction: Circulating chromogranin A(CgA) is considered a useful marker for gastroenteropancreatic endocrine tumors. Data on its pattern in MEN-1 patients with non-functioning pancreatic tumors(NFPT) are scant.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Roberta E Rossi
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.